Wim Souverijns
Corporate Officer/Principal at PHARVARIS N.V.
Net worth: 2 M $ as of 2024-04-29
Network origin in Wim Souverijns first degree
Entity | Entity type | Industry | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 18 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Wim Souverijns via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
PORTAGE BIOTECH INC. | Biotechnology | Director/Board Member | |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Top Institute Pharma
Top Institute Pharma BiotechnologyHealth Technology Part of Center for Translational Molecular Medicine, Top Institute Pharma provides pharmaceutical research services. The company is based in Leiden, Netherlands. Top Institute Pharma was acquired by Center for Translational Molecular Medicine on June 09, 2015. | Biotechnology | Director/Board Member | |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
LSP Management Group BV
LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Investment Managers | Founder | |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
Chalmers University of Technology | College/University | Director/Board Member | |
University of Uppsala | College/University | Corporate Officer/Principal | |
DBV TECHNOLOGIES | Pharmaceuticals: Major | Director/Board Member General Counsel | |
The Rockefeller University | College/University | Corporate Officer/Principal | |
University of Utrecht | College/University | Doctorate Degree | |
Swiss Federal Institute of Technology | College/University | Doctorate Degree Doctorate Degree | |
Credit Suisse Securities (USA) LLC
Credit Suisse Securities (USA) LLC Regional BanksFinance Credit Suisse Securities (USA) LLC provides a variety of capital raising, market making, advisory and brokerage services for governments, financial institutions, high-net-worth individuals, and corporate clients and affiliates. It is also a primary dealer in U.S. government securities and an underwriter, placement agent, and dealer for money market instruments, commercial paper, mortgage and other assetbacked securities, as well as a range of debt, equity and other convertible securities of corporations and other issuers. The company was founded on January 3, 2003 and is headquartered in New York, NY. | Regional Banks | Director/Board Member | |
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Genzyme Europe BV
Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The company is based in Amsterdam, Netherlands. | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing | |
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
Organon International BV | President | ||
HANSA BIOPHARMA AB | Pharmaceuticals: Major | Director/Board Member | |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
Complix NV
Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Pharmaceuticals: Major | Chairman | |
Weill Cornell Medical College | College/University | Corporate Officer/Principal | |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | Biotechnology | Chairman | |
Harvard Medical School | College/University | Doctorate Degree | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
VICORE PHARMA HOLDING AB | Pharmaceuticals: Major | Chairman Director/Board Member | |
Uppsala University Hospital
Uppsala University Hospital Hospital/Nursing ManagementHealth Services Uppsala University Hospital operates a hospital. | Hospital/Nursing Management | Corporate Officer/Principal | |
Top Sector Life Sciences & Health | Director/Board Member | ||
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Chairman | |
Harvard College | College/University | Undergraduate Degree | |
Nefarma | Director/Board Member | ||
Microbiotica Ltd.
Microbiotica Ltd. BiotechnologyHealth Technology Microbiotica Ltd. performs research and experimental development on biotechnology. The company was founded by Michael Anthony Romanos, Trevor David Lawley and Gordon Dougan in December 2016 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chairman | |
ROCKET PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
INIM Pharma AB
INIM Pharma AB Pharmaceuticals: MajorHealth Technology INIM Pharma AB operates as drug development company that focuses on the development of immunomodulatory drugs for interstitial lung diseases. It develops a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. The company was founded by Carl-Johan Dalsgaard and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
Bank of America Merrill Lynch (New York) | Corporate Officer/Principal | ||
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | Pharmaceuticals: Major | Director/Board Member | |
Vico Therapeutics BV
Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member | |
Jubilant Therapeutics, Inc.
Jubilant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Jubilant Therapeutics, Inc. operates as a patient-centric biopharmaceutical company. The firm uses advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. The company is headquartered in Bedminster, NJ. | Pharmaceuticals: Major | Director/Board Member | |
Umoja Biopharma, Inc.
Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Director/Board Member | |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
Pharvaris GmbH
Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member Founder Founder Director/Board Member Chairman Director/Board Member Founder Founder | |
Kosa Pharma GmbH | Founder Founder | ||
Rfidcompare Europe AB | Director/Board Member | ||
Enavate Sciences
Enavate Sciences Financial ConglomeratesFinance Enavate Sciences is a platform created by Patient Square Capital to support therapeutic companies in advancing medicines and enabling technologies to address patient needs. The company is based in Delaware. Enavate strives to empower a diverse portfolio of therapeutic companies to accelerate innovation through capital support and operational experience. James P. Boylan has been the CEO of the American company since 2022. | Financial Conglomerates | Private Equity Investor |
Statistics
International
United States | 15 |
Netherlands | 13 |
Sweden | 10 |
Switzerland | 6 |
United Kingdom | 4 |
Sectoral
Health Technology | 30 |
Consumer Services | 9 |
Finance | 5 |
Commercial Services | 3 |
Health Services | 2 |
Operational
Director/Board Member | 114 |
Corporate Officer/Principal | 36 |
Independent Dir/Board Member | 32 |
Founder | 15 |
Chairman | 13 |
Most connected contacts
Insiders | |
---|---|
Martijn Kleijwegt | 33 |
Rémi Droller | 29 |
Berndt A. E. Modig | 23 |
Johannes G. C. P. Schikan | 22 |
Viviane Monges | 21 |
David Meeker | 19 |
Robert Glassman | 16 |
Margareta Elisabeth Björk | 12 |
Jochen Knolle | 11 |
Joan Schmidt | 7 |
Anne Marie de Jonge Schuermans | 6 |
Anne Lesage | 5 |
Morgan Conn | 5 |
Anna Nijdam | 5 |
Peng Lu | 4 |
- Stock Market
- Insiders
- Wim Souverijns
- Company connections